Prescient Therapeutics - $15.8m in Cash
Prescient Therapeutics reported a stable financial quarter ending March 2024 with $15.8 million in cash reserves, aligning with budget expectations, and significant progress in the clinical development of PTX-100 for T-cell lymphomas, including favorable Phase 1b study results presented at a specialist conference.